Feasibility of Histotripsy to Treat Infections on Surgical Mesh

Iowa State University, Ames IA

Investigators

Linked publications, trials & patents

Abstract

? DESCRIPTION (provided by applicant): There is a critical need to develop a new device to noninvasively treat mesh infections without removing the mesh. In the absence of such a device, the treatment of mesh infections will remain highly invasive and costly. This study's objective is to optimize cavitation-based histotripsy to treat surgical mesh infections. Histotrips generates/excites a cloud of micron sized bubbles in the tissue which mechanically shred the targeted cells. The physics of microbubble collapse promotes lysis of bacteria attached to the implant enhancing the destruction of the bacteria biofilm causing the infection. Specific Aim #1: Verify biofilm destruction on a mesh target. Our preliminary studies treated biofilms on planar surfaces. The working hypothesis is that the ultrasound will be equally effective at treating biofilms on the mesh structure. This hypothesis will be tested by in vitro and in vivo experiments where infected meshes will be treated with ultrasound induced cavitation under varying exposure conditions. Specific Aim #2: Evaluate the impact of the therapy on mesh functionality. With infection, the fibrous tissue disintegrates at the site of infection and the mesh loosens. Further loosening in the short term might also occur in the vicinity of the mesh from the histotripsy exposure. However, if the extent of damage is small (i.e., less than a few millimeters), then we hypothesize the tissue will heal around the mesh as is expected during normal implantation following the treatment. This hypothesis will be tested using a rabbit peritoneal mesh infection model. This project is significant because once developed thousands of patients each year would have an alternative to invasive surgery for treating mesh infections. The proposed research is innovative because it will potentially provide a noninvasive treatment option where there are no other alternatives currently.